1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

  • June 2015
  • ID: 3090976
  • Format: PDF
  • By Firstword Pharma

Summary








The question of whether to approve Regeneron and Sanofi’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab) never really seemed to be in doubt at FDA’s Endocrinologic and Metabolic Drugs Advisory Committee meetings on Tuesday and Wednesday, as panel members by and large expressed comfort with the safety and efficacy profiles of the respective anti-PCSK9 mAbs to treat dyslipidaemia.

Rather, the committees appeared to be more concerned about what specific groups of patients the agents should be approved for, which is an issue of high importance to physicians and patients, as well as the payers (and pharmacy benefit managers) that may ultimately serve as the gatekeeper for deciding who does and does not receive an anti-PCSK9 agent.

CVS and Express Scripts, which are in charge of making formulary decisions for millions of Americans, may have found the committee discussions rather encouraging based on the obvious anxiety articulated by a number of panellists who said it would be premature to prescribe Praluent or Repatha for patients with run-of-the-mill hypercholesterolaemia before the results from ongoing cardiovascular outcome trials (CVOT) become available in 2017 or so.

Assuming the FDA heeds the committee’s advice and approves the agents for use only in patients with familiar hypercholesterolaemia (FH), and possibly also in high-risk patients not achieving LDL goals on statins – roughly in line with Repatha’s label in the EU – this would remove, for the time being anyway, the possible doomsday scenario outlined by CVS in February, when the PBM warned that spending on anti-PCSK9 mAbs would hit $150 billion per year.

But to whom exactly will physicians decide to prescribe Praluent and Repatha, and how will they decide between them?

Analysts suggest the biggest differentiating factor between the products is Regeneron and Sanofi’s decision to test both a low- and high-dose versions of Praluent, which could give physicians who may not necessarily be comfortable with patients achieving very low LDL levels the added flexibility of starting with the lower, potentially cheaper dose and moving up to the higher dose only if necessary. Amgen, on the other hand, will be able to tout a once-monthly regimen of Repatha (along with a biweekly regimen), which some patients may prefer rather than Praluent, which would only be available as a biweekly injection.










To gain better understanding about how the panel discussion has shaped their views on the two products, FirstWord PLUS is polling US- and/or EU5-based cardiologists and asking them…




Praluent’s dosing flexibility (ie, the availability of a high and lose dose to allow for titration) has been highlighted as a potential differentiating factor between it and fellow anti-PCSK9 mAb, Repatha, particularly for doctors who are not comfortable with patients having “very low” LDL levels. Might this make you any more likely to prescribe Praluent rather than Repatha?
It has been suggested that the manufacturers of Praluent may seek to take advantage of having a two-dose levels by pricing the low-dose option well below both the high-dose and ostensibly Repatha. If this turns out to be the case, how important would it be in deciding which anti-PCSK9 mAb to prescribe?
FDA panel members were slightly more critical about the safety profile of Repatha due to Amgen’s shorter clinical trials (12 weeks). How concerned are you that the agent’s safety may be meaningfully different than Praluent?
What factors will be most important when it comes time to decide between prescribing Praluent or Repatha?
Assuming the FDA approves both agents with labels that allow for use in high-risk (non-FH) patients not achieving LDL goal on statin therapy, to what percentage of these patients would you expect to prescribe an anti-PCSK9 mAb within one year of launch?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019, provides an overview ...

Lymphoma Treatment Drugs Markets in China

Lymphoma Treatment Drugs Markets in China

  • $ 4000
  • October 2019

China’s demand for Lymphoma Treatment Drugs has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

Hydroquinone Market, Size, Share, Outlook and Growth Opportunities 2019-2025

Hydroquinone Market, Size, Share, Outlook and Growth Opportunities 2019-2025

  • $ 4580
  • September 2019

Hydroquinone Market, Size, Share, Outlook and Growth Opportunities 2019-2025Hydroquinone market outlook report presents key insights into global Hydroquinone markets and companies with emphasis on market ...


ref:plp2015

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on